• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4610647)   Today's Articles (47)   Subscriber (49380)
For: Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003;57:80-92. [PMID: 12886526 DOI: 10.1002/pros.10276] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Number Cited by Other Article(s)
1
Hawlina S, Zorec R, Chowdhury HH. Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer. Life (Basel) 2023;13:1498. [PMID: 37511873 PMCID: PMC10382052 DOI: 10.3390/life13071498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 06/28/2023] [Accepted: 06/29/2023] [Indexed: 07/30/2023]  Open
2
Saleh OM, Albakri KA, Alabdallat YJ, Dajani MH, El Gazzar WB. The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review. Biomarkers 2021;27:22-34. [PMID: 34882051 DOI: 10.1080/1354750x.2021.2016973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
3
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 2021;601:617-622. [PMID: 34814158 PMCID: PMC8791831 DOI: 10.1038/s41586-021-04232-5] [Citation(s) in RCA: 134] [Impact Index Per Article: 44.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 11/11/2021] [Indexed: 11/08/2022]
4
Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2021;1:1557-1576. [PMID: 23264902 PMCID: PMC3525611 DOI: 10.4161/onci.22428] [Citation(s) in RCA: 74] [Impact Index Per Article: 24.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]  Open
5
Gao Q, Su X, Annabi MH, Schreiter BR, Prince T, Ackerman A, Morgas S, Mata V, Williams H, Lee WY. Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer. Clin Genitourin Cancer 2019;17:183-190. [PMID: 30853355 DOI: 10.1016/j.clgc.2019.02.003] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2018] [Revised: 02/04/2019] [Accepted: 02/05/2019] [Indexed: 12/13/2022]
6
Noguchi M, Koga N, Igawa T, Itoh K. Clinical development of immunotherapy for prostate cancer. Int J Urol 2017. [PMID: 28636142 DOI: 10.1111/iju.13397] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
7
Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat Rev Urol 2017;14:501-510. [DOI: 10.1038/nrurol.2017.77] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
8
Sakamoto S, Noguchi M, Yamada A, Itoh K, Sasada T. Prospect and progress of personalized peptide vaccinations for advanced cancers. Expert Opin Biol Ther 2016;16:689-98. [PMID: 26938083 DOI: 10.1517/14712598.2016.1161752] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
9
Whitmill A, Timani KA, Liu Y, He JJ. Tip110: Physical properties, primary structure, and biological functions. Life Sci 2016;149:79-95. [PMID: 26896687 DOI: 10.1016/j.lfs.2016.02.062] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2015] [Revised: 02/11/2016] [Accepted: 02/15/2016] [Indexed: 12/11/2022]
10
Noguchi M, Moriya F, Koga N, Matsueda S, Sasada T, Yamada A, Kakuma T, Itoh K. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother 2016;65:151-60. [PMID: 26728480 PMCID: PMC11028889 DOI: 10.1007/s00262-015-1781-6] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Accepted: 12/11/2015] [Indexed: 01/21/2023]
11
Yoshimura K, Minami T, Nozawa M, Kimura T, Egawa S, Fujimoto H, Yamada A, Itoh K, Uemura H. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer. Eur Urol 2016;70:35-41. [PMID: 26782346 DOI: 10.1016/j.eururo.2015.12.050] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Accepted: 12/29/2015] [Indexed: 11/27/2022]
12
Noguchi M, Koga N, Moriya F, Itoh K. Immunotherapy in prostate cancer: challenges and opportunities. Immunotherapy 2016;8:69-77. [DOI: 10.2217/imt.15.101] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]  Open
13
Barach YS, Lee JS, Zang X. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med 2015;17:47-55. [PMID: 20971039 DOI: 10.1016/j.molmed.2010.09.006] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2010] [Revised: 09/23/2010] [Accepted: 09/23/2010] [Indexed: 12/31/2022]
14
Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Immunol Lett 2014;161:20-30. [PMID: 24794408 DOI: 10.1016/j.imlet.2014.04.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Revised: 03/31/2014] [Accepted: 04/16/2014] [Indexed: 12/22/2022]
15
Liu F, Zhang H, Shen D, Wang S, Ye Y, Chen H, Pang X, Song Q, He P. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1. J Gastroenterol 2014;49:419-26. [PMID: 23604623 DOI: 10.1007/s00535-013-0811-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2012] [Accepted: 04/02/2013] [Indexed: 02/04/2023]
16
Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert Rev Vaccines 2014;11:857-68. [DOI: 10.1586/erv.12.54] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
17
Noguchi M, Moriya F, Suekane S, Ohnishi R, Matsueda S, Sasada T, Yamada A, Itoh K. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time. BMC Cancer 2013;13:613. [PMID: 24373380 PMCID: PMC3882108 DOI: 10.1186/1471-2407-13-613] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2013] [Accepted: 09/03/2013] [Indexed: 11/16/2022]  Open
18
Takao Y, Yamada A, Yutani S, Sata M, Itoh K. Antibody Reactive to a Hepatitis C Virus (HCV)-Derived Peptide Capable of Inducing HLA-A2 Restricted Cytotoxic T Lymphocytes Is Detectable in a Majority of HCV-Infected Individuals without HLA-A2 Restriction. Microbiol Immunol 2013;48:507-17. [PMID: 15272196 DOI: 10.1111/j.1348-0421.2004.tb03546.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
19
Dong L, Zhang X, Ren J, Wu S, Yu T, Hou L, Fu L, Yi S, Yu C. Human Prostate Stem Cell Antigen and HSP70 Fusion Protein Vaccine Inhibits Prostate Stem Cell Antigen-Expressing Tumor Growth in Mice. Cancer Biother Radiopharm 2013;28:391-7. [DOI: 10.1089/cbr.2012.1357] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
20
Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother 2013;62:919-29. [PMID: 23197273 PMCID: PMC11029009 DOI: 10.1007/s00262-012-1379-1] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2012] [Accepted: 11/16/2012] [Indexed: 12/19/2022]
21
Thelin MA, Bartolini B, Axelsson J, Gustafsson R, Tykesson E, Pera E, Oldberg Å, Maccarana M, Malmstrom A. Biological functions of iduronic acid in chondroitin/dermatan sulfate. FEBS J 2013;280:2431-46. [PMID: 23441919 PMCID: PMC3717172 DOI: 10.1111/febs.12214] [Citation(s) in RCA: 94] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2012] [Revised: 02/17/2013] [Accepted: 02/18/2013] [Indexed: 01/08/2023]
22
Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci 2012;104:15-21. [PMID: 23107418 DOI: 10.1111/cas.12050] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Revised: 10/18/2012] [Accepted: 10/22/2012] [Indexed: 12/17/2022]  Open
23
Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, Sasada T, Yamada A, Itoh K. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate 2012;72:834-45. [PMID: 21932426 DOI: 10.1002/pros.21485] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Accepted: 08/22/2011] [Indexed: 02/01/2023]
24
Thelin MA, Svensson KJ, Shi X, Bagher M, Axelsson J, Isinger-Ekstrand A, van Kuppevelt TH, Johansson J, Nilbert M, Zaia J, Belting M, Maccarana M, Malmström A. Dermatan sulfate is involved in the tumorigenic properties of esophagus squamous cell carcinoma. Cancer Res 2012;72:1943-52. [PMID: 22350411 DOI: 10.1158/0008-5472.can-11-1351] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
25
DNA vaccination: using the patient's immune system to overcome cancer. Clin Dev Immunol 2010;2010:169484. [PMID: 21197271 PMCID: PMC3010826 DOI: 10.1155/2010/169484] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2010] [Revised: 10/08/2010] [Accepted: 10/21/2010] [Indexed: 12/15/2022]
26
Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K. Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. Exp Ther Med 2010;2:109-117. [PMID: 22977478 DOI: 10.3892/etm.2010.177] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2010] [Accepted: 12/02/2010] [Indexed: 11/06/2022]  Open
27
Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010;59:1001-9. [PMID: 20146063 PMCID: PMC11030921 DOI: 10.1007/s00262-010-0822-4] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2009] [Accepted: 01/25/2010] [Indexed: 10/19/2022]
28
Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, Escara-Wilke J, Leander KR, Defeo-Jones D, Hwang C, Sanda MG. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate 2010;70:1002-11. [PMID: 20209643 PMCID: PMC2875372 DOI: 10.1002/pros.21134] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
29
Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 2010;27 Suppl 6:G52-9. [PMID: 20006141 DOI: 10.1016/j.vaccine.2009.09.106] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2009] [Accepted: 09/24/2009] [Indexed: 12/15/2022]
30
Uemura H, Fujimoto K, Mine T, Uejima S, de Velasco MA, Hirao Y, Komatsu N, Yamada A, Itoh K. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Sci 2010;101:601-8. [PMID: 20128819 PMCID: PMC11159476 DOI: 10.1111/j.1349-7006.2009.01459.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2024]  Open
31
Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jäger E. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 2010;126:909-18. [PMID: 19728336 DOI: 10.1002/ijc.24850] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
32
Kanaly CW, Ding D, Heimberger AB, Sampson JH. Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am 2009;21:95-109. [PMID: 19944970 DOI: 10.1016/j.nec.2009.09.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
33
Terasaki Y, Shichijo S, Niu Y, Komatsu N, Noguchi M, Todo S, Itoh K. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol Immunother 2009;58:1877-85. [PMID: 19330328 PMCID: PMC11030184 DOI: 10.1007/s00262-009-0699-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2008] [Accepted: 03/12/2009] [Indexed: 10/21/2022]
34
Aoki M, Ueda S, Nishikawa H, Kitano S, Hirayama M, Ikeda H, Toyoda H, Tanaka K, Kanai M, Takabayashi A, Imai H, Shiraishi T, Sato E, Wada H, Nakayama E, Takei Y, Katayama N, Shiku H, Kageyama S. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine 2009;27:6854-61. [PMID: 19761832 DOI: 10.1016/j.vaccine.2009.09.018] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2009] [Revised: 09/01/2009] [Accepted: 09/02/2009] [Indexed: 10/20/2022]
35
Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti‐peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scandinavian Journal of Clinical and Laboratory Investigation 2009;64:535-45. [PMID: 15370458 DOI: 10.1080/00365510410007008] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
36
Immunogenicity in peptide-immunotherapy: from self/nonself to similar/dissimilar sequences. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2008;640:198-207. [PMID: 19065793 DOI: 10.1007/978-0-387-09789-3_15] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
37
Naito M, Itoh K, Komatsu N, Yamashita Y, Shirakusa T, Yamada A, Moriya F, Ayatuka H, Mohamed ER, Matsuoka K, Noguchi M. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate 2008;68:1753-62. [PMID: 18767041 DOI: 10.1002/pros.20847] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
38
Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2008;16:96-103. [PMID: 19020110 DOI: 10.1128/cvi.00274-08] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
39
Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother 2008;57:1301-13. [PMID: 18273616 PMCID: PMC11030952 DOI: 10.1007/s00262-008-0463-z] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2007] [Accepted: 01/24/2008] [Indexed: 01/10/2023]
40
Epel M, Carmi I, Soueid-Baumgarten S, Oh S, Bera T, Pastan I, Berzofsky J, Reiter Y. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol 2008;38:1706-20. [PMID: 18446790 PMCID: PMC2682370 DOI: 10.1002/eji.200737524] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
41
Garcia-Hernandez MDLL, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008;68:861-9. [PMID: 18245488 DOI: 10.1158/0008-5472.can-07-0445] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
42
Thomas-Kaskel AK, Veelken H. [Active immunotherapy of prostate cancer with a focus on dendritic cells]. Actas Urol Esp 2007;31:668-79. [PMID: 17896564 DOI: 10.1016/s0210-4806(07)73704-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
43
Noguchi M, Yao A, Harada M, Nakashima O, Komohara Y, Yamada S, Itoh K, Matsuoka K. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007;67:933-42. [PMID: 17440952 DOI: 10.1002/pros.20572] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
44
Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 2007;56:689-98. [PMID: 16937115 PMCID: PMC11030603 DOI: 10.1007/s00262-006-0216-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2006] [Accepted: 07/25/2006] [Indexed: 10/24/2022]
45
Marrari A, Iero M, Pilla L, Villa S, Salvioni R, Valdagni R, Parmiani G, Rivoltini L. Vaccination therapy in prostate cancer. Cancer Immunol Immunother 2007;56:429-45. [PMID: 17031640 PMCID: PMC11030671 DOI: 10.1007/s00262-006-0233-8] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2006] [Accepted: 09/07/2006] [Indexed: 01/05/2023]
46
Takao Y, Yamada A, Yutani S, Takedatsu H, Ono T, Etoh K, Wang Y, Suzuki S, Ide T, Shimotohno K, Sata M, Itoh K. Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b(+) HLA-A24(+) patients. Hepatol Res 2007;37:186-95. [PMID: 17362301 DOI: 10.1111/j.1872-034x.2007.00018.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
47
Garcia-Hernandez MDLL, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007;67:1344-51. [PMID: 17283172 DOI: 10.1158/0008-5472.can-06-2996] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
48
Takao Y, Yamada A, Yutani S, Ono T, Nagao Y, Ando E, Ide T, Itoh K, Sata M. Serum levels of IgG to the peptide of HCV1b core at positions 35-44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132-2140 correlated with better prognosis in HCV-infected patients. Med Microbiol Immunol 2007;196:157-64. [PMID: 17574493 DOI: 10.1007/s00430-007-0038-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2006] [Indexed: 01/21/2023]
49
Machlenkin A, Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother 2007;56:217-26. [PMID: 16738849 PMCID: PMC11030074 DOI: 10.1007/s00262-006-0184-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2006] [Accepted: 04/12/2006] [Indexed: 12/11/2022]
50
Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007;56:81-7. [PMID: 16362411 PMCID: PMC11041923 DOI: 10.1007/s00262-005-0110-x] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2005] [Accepted: 11/25/2005] [Indexed: 10/25/2022]
PrevPage 1 of 2 12Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA